Bright Minds Biosciences (DRUG) Income towards Parent Company (2023 - 2024)
Bright Minds Biosciences' (DRUG) quarterly Income towards Parent Company came in at $35513.3 in Q4 2024, up 102.87% YoY from $17505.4 in Q1 2024, and down 78.87% on a QoQ basis from $168091.4 in Q2 2024.
Bright Minds Biosciences (DRUG) Income towards Parent Company (2023 - 2024) Analysis & Trends
Bright Minds Biosciences (DRUG) has 2 years of Income towards Parent Company data on file, last reported at $35513.3 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bright Minds Biosciences | 733.05 Mn | 733.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 35,513.28 |
| Jun 30, 2024 | 168,091.41 |
| Dec 31, 2023 | -1.24 Mn |
| Jun 30, 2023 | -1.09 Mn |